REFERENCES
1. Eelen G, Treps L, Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ Res 2020;127:310-29.
2. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999;1:293-302.
3. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
4. Ribatti D. Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon? Leukemia 2009;23:433-4.
5. Testa U, Saulle E, Castelli G, Pelosi E. Endothelial progenitor cells in hematological malignancies. Stem Cell Invest 2016;3:26.
6. Marcu R, Choi YJ, Xue J, et al. Human organ-specific endothetial cell heterogeneity. IScience 2018;4:20-35.
7. Qiu J, Hirschi KK. Endothelial cell development and its application to regenerative medicine. Circulation Res 2019;125:489-501.
8. Plein A, Fantin A, Denti L, Pollard JW, Ruhberg C. Erythro-myeloid progenitors contribute endothelial cells to blood vessels. Nature 2018;562:223-8.
9. McDonald AI, Shirali AS, Aragon R, et al. Endothelial regeneration of large vessels is a biphasic process driven by local cells with distinct proliferative capacities. Cell Stem Cell 2018;23:210-25.
10. Wakabayashi T, Naito H, Suehiro JI, et al. CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative properties. Cell Stem Cell 2018;22:384-97.
11. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Med 2011;17:1359-69.
12. Testa U, Pelosi E, Castelli G. Endothelial progenitors in the tumor microenvironment. Adv Exp Med Biol 2020;1263:85-115.
13. Kumar S, Sharife H, Kreisel T, et al. Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity. Cell Metab 2019;30:1-11.
14. Chen J, Hendriks M, Chatzis A, Ramasamy SK, Kusumbe AP. Bone vasculature and bone marrow vascular niches in health and disease. J Bone Min Res 2020;35:2103-20.
15. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014;507:323-8.
16. Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014;508:269-73.
17. Filipowska J, Tomaczewski KA, Niedzwiedzki L, Walocha JA, Niedzwedzki T. The role of vasculature in bone development, regeneration and proper systemic functioning. Angiogenesis 2017;20:291-302.
18. Ramasamu SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 2014;507:376-80.
19. Ramasamy SK, Kusumbe AP, Schiller M, et al. Blood flow controls bone vascular function and osteogenesis. Nat Commun 2016;7:13601.
20. Xu CL, Gao X, Wei QZ, Nakahara F, et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nat Commun 2018;9:2449.
21. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelila and perivascular cells maintain hematopoietic stem eclls. Nature 2012;481:457-62.
22. Kenswil KJG, Jaramillo AC, Ping Z, et al. Characterization of endothelial cells associated with hematopoietic niche formation in humans identifies IL-33 as an anabolic factor. Cell Rep 2018;22:666-78.
23. Himburg HA, Termini CM, Schlussel L, et al. Distinct bone marrow sources of pleiotrophin control hematopoietic stem cell maintenance and regeneration. Cell Stem Cell 2018;23:370-81.
24. Chen Q, Liu Y, Jeong HW, et al. Apelin+ endothelial niche cells control hematopoiesis and mediate vascular regeneration after myeloablative injury. Cell Stem Cell 2019;25:768-83.
25. Mokhtari S, Colletti E, Yin WH, et al. A human bone marrow mesodermal-derived cell population with hemogenic potential. Leukemia 2018;32:1575-86.
26. Mitroulis I, Chen LS, Singh RP, et al. Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. J Clin Invest 2017;127:3624-39.
27. Passaro D, Di Tullio A, Abarrategi A, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 2017;32:324-41.
28. Itkin T, Gur-Cohen S, Spencer JA, et al. Distinct bone marrow blood vessels differentially regulate hematopoiesis. Nature 2016;532:323-8.
29. Kusumbe AP, Ramasamy SK, Itkin T, et al. Age-dependent modulation of vascular niches for haematopoietic stem cells. Nature 2016;532:380-4.
30. Dar A, Goichberg P, Shinder V, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol 2005;6:1038-47.
31. Lévesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;110:187-96.
32. Kim HK, Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108:812-20.
33. Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 2003;31:1126-34.
34. Singh P, Hoggatt J, Kamocka M, et al. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. J Clin Invest 2017;127:4527-40.
35. Boettcher S, Gerosa RC, Redpour R, et al. Endothelial cells translate pathogen signals into G-CSF-driven emergency gran ulopoiesis. Blood 2014;124:1393-403.
36. Prendergast A, Kuck A, van Essen M, Haas S, Blaskiewicz S, Essers MAG. IFNα-mediated remodeling of endothelial cells in the bone marrow niche. Haematologica 2017;102:445-53.
37. Duarte D, Hawkins ED, Akinduro O, et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 2018;22:64-77.
38. Le PM, Andreef M, Battula VL. Ostogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica 2018;103:1945-55.
39. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005;106:1232-9.
40. Liersch R, Gerss J, Schliemann C, et al. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 2012;119:5215-20.
41. Winkler IG, Barbier V, Nowlan B, et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self-renewal and chemoresistance. Nat Med 2012;18:1651-61.
42. Spikins DA, Wei XB, Wei JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005;435:969-73.
43. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007;25:1315-21.
44. Ninomiya M, Abe A, Katsumi A, et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007;21:136-42.
45. Winkler IG, Barbier V, Pattabiraman DR, Gonda TJ, Magani JL, Levesque JP. Vascular niche E-Selectin protects acute myeloid leukemia stem cells from chemotherapy. Blood 2014;124:620.
46. Winkler IG, Barbier V, Tay MJ, et al. Blocking vascular niche E-selectin dampens AML stem cell regeneration/survival potential in vivo by inhibiting MAPK/ERK and PI3K/AKT signaling pathways. Blood 2019;134:2657.
47. Barbier V, Erbani J, Fiveash C, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nast Commun 2020;11:2042.
48. Erbani J, Tay J, Barbier V, Levesque JP, Winkler IG. Acute myeloid leukemia chemo-resistance is mediated by E-selectin receptor CD162 in bone marrow niches. Front Cell Dev Biol 2020;8:668.
49. Godavarthy PS, Kumar R, Herkt SC, et al. The vascular bone marriw niche influences outcome in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis. Haematologica 2020;105:136-47.
50. Krause DS, Lazarides K, von Adrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006;12:1175-80.
51. Padrò T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44.
52. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13.
53. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001;97:3919-24.
54. Padrò T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10.
55. Ghannadan M, Wimazal F, Simonitsch I, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003;119:663-71.
56. Jothlingam P, Basu D, Dutta TK. Angiogenesis and proliferation index in patients with acute myeloid leukemia: a prospective study. Bone Marrow Res 2014;2014:634874.
57. Song YQ, Tan Y, Liu LB, Wang Q, Zhu J, Liu M. Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia. Oncology Lett 2015;10:211-5.
58. Kuzu I, Beksac M, Arat M, Celebi H, Elhan H, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 2004;45:1185-90.
59. Weidenaar AC, ter Elst A, Koopmans-Klein G, et al. High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol 2011;34:289-96.
60. Aguayo A, Kantarjian H, Gidel C, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
61. Chand R, Chandra H, Chandra S, Verma SK. Role of microvessel density and vascular endothelial growth factor in angiogenesis of hematological malignancies. Bone Marrow Res 2016;5043383.
62. Song MZ, Wang HP, Ye QL. Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis. Syst Rev 2020;9:103.
63. Guo BP, Liu Y, Tan XH, Cen H. Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis. Leuk Lymphoma 2013;54:1418-25.
64. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002;95:1923-30.
65. De Bont ES, Fidler V, Meeuwseen T, Scherpen F, Hahlen K, Kmaops WA. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-61.
66. Rabitsch W, Sperr WR, Lechner K, et al. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma 2004;45:1369-73.
67. Savic A, Cemericik-Martinovic V, Dovat S, et al. Angiogenesis and survival in patients with myelodysplastic syndrome. Pathol Oncol Res 2012;18:681-90.
69. Mohammadisl J, Khosravi A, Shahjahani M, Azizidoost S, Saki N. Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia. J Cancer Metast Treat 2016;2:44-50.
70. Frietschj JJ, Huntstig F, Wittke C, et al. Extra-medullary recurrence of myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant 2020. in press
71. Piccaluga PP, Paolini S, Navari M, Etebari M, Visani G, Ascani S. Increased angiogenesis seems to correlate with inferior overall survival. Pol J Pathol 2018;69:254-65.
72. Hiramatsu A, Miwa H, Shikami M, et al. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor if VEGF in t(15;17) AML and VEGF/type 2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 2006;47:89-95.
73. Imai N, Shikami M, Miwa H, Suganuma K. T(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type 2 pathway and phosphorylation of Akt. Brit J Haematol 2006;135:673-82.
74. Ter Elst A, Ma B, Scherpen F, et al. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 2011;71:2761-71.
75. Saulle E, Petronelli A, Pelosi E, et al. PML-RAR alpha induces the downmodulation of HHEX: a kay event responsible for the induction of an angiogenetic response. J Hematol Oncol 2016;9:33.
76. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF /VEGF-R2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 2001;98:10857-62.
77. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Luekemia 2003;17:604-11.
78. Zahiragic L, Schliemann C, Bieker R, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007;21:1310-2.
79. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-7.
80. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
81. Nobrega-Pereeira S, Caiado F, et al. VEGFR2-mediated reprogramming of mitochondrial metabolism regulates the sensitivity of acute myeloid leukemia to chemotherapy. Cancer Res 2018;78:731-41.
82. Zhao D, Hou H, Zhang XC. Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets Ther 2018;11:4137-47.
83. Yu L, Deng MM, Li ZF, Fang ZH, Dai Y, Xu B. Apatinib exhibits cytotoxicity to acute myeloid leukemia cell via targeting VEGFR2-mediated pro-survival signaling and angiogenesis. Blood 2019;134:51548.
84. Deng MM, Zha J, Zhao HJ, et al. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-nediated prosurvival signaling and angiogenesis. Exp Cell Res 2020;390:111934.
85. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62-8.
86. Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukemia (SORAML): a multicentre, phase 2, randomized controlled trial. Lancet Oncol 2015;16:1691-9.
87. Sharinen P, Eklund L, Alitalo K. Therapeutic targeting of angiopoietin-TIE pathway. Nat Rev Drug Discov 2017;16:635-51.
88. Jeansson M, Gawlik A, Anderson G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011;121:2278-89.
89. Daly C, Pasnikowski E, Burova E, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 2006;103:15491-96.
90. Daly C, Eichten A, Castanero C, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013;73:108-18.
91. Watarai M, Miwa H, Shikami M, et al. Expression of endothelial cell-associated molecules in AML cells. Leukemia 2002;16:112-9.
92. Schliemann C, Bieker R, Padro T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006;91:1203-11.
93. Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007;21:1901-6.
94. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005;23:1109-17.
95. Riccioni R, Diverio D, Mariani G, et al. Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells 2007;25:1862-71.
96. Lewis CE, De Palma M, Naldini L. Tie-2 expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 2009;67:8429-32.
97. Riccioni R, Pelosi E, Riti V, Castelli G, Lo-Coco F, Testa U. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. Br J Haematol 2011;153:33-42.
98. Bchegowda L, Morrone K, Winski SL, et al. Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Res 2016;76:4841-9.
99. Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood 2012;119:1345-52.
100. Hong G, Kuek V, Shi JX, et al. EGFL7: master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. J Cell Physiol 2018;233:8526-37.
101. Papaioiannou D, Shen CX, Nicolet D, et al. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A 2017;114:E4641-7.
102. Chen ZH, Dai YF, Pang YF, et al. High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Cancer Biol Ther 2019;20:1314-8.
